# PFE — Pfizer Inc.

## Company & Research Metadata

- **Company:** Pfizer Inc.
- **Ticker:** PFE
- **Exchange:** NYSE
- **Sector / Industry:** Health Care / pharmaceuticals
- **Template version:** 2.7
- **Research date:** 2026-10-21
- **Valuation / score price snapshot:** $30.00 — 2026-11-03 regular-session close, America/New_York
- **Tracking tier:** Primary Watchlist
- **Owned:** Yes
- **Primary operating period reviewed:** Q2 2026
- **Historical period reviewed:** TTM, FY 2025, FY 2024; latest balance-sheet date shown below
- **Latest investor presentation reviewed:** Results release and associated financial tables; no separate slide deck materially used
- **Latest earnings call reviewed:** Q2 2026, complete material Q&A
- **Latest post-earnings management commentary reviewed:** No separate later management presentation incorporated

- **Price snapshot date:** 2026-11-03

- **Price snapshot time / timezone:** Regular-session close, America/New_York (including exchange half-days)
- **Competitor / analyst-Q&A audit:** 2026-10-28; original operating, price and valuation snapshots retained.

## What's Changed Since Previous Review

**Current Review:** 2026-10-28

**Previous Review:** 2026-10-21

**Update Trigger:** Competitor relevance and analyst-Q&A correction

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Competition | Preceding operating and comparable-company classifications | Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors | Corrects the competitive comparison; does not by itself re-underwrite the valuation |
| Analyst questions | Prior source-linked Q&A summaries | Complete questions and sentence-form management answers; all 9 existing rows retained | Improves readability while preserving the recorded exchange meaning |
| Valuation and scores | Approved operating/price snapshots, scenarios, scores and decisions | Preserved | No price refresh, rerank or change to valuation assumptions in this correction pass |

**Thesis:** No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $30.00 — 2026-11-03 regular-session close, America/New_York |
| Rating / Zone Status | Hold / Watch |
| Bear / Base / Bull Fair Value | $15.61 / $29.71 / $48.93 |
| Scenario Probabilities | 30% / 50% / 20% |
| Probability-Weighted Fair Value | $29.32 |
| Probability-Weighted Expected Return | -2.3% |
| Bear-Case Return | -48.0% |
| Strong Buy Zone | ≤ $17.17 |
| Buy Zone | >$17.17–$23.46 |
| Avoid Chasing Above | > $32.58 |
| Quality Score / Tier | 68.2 / Tier B |
| Opportunity Score / Rank | 45.3 / #51 of 76 |
| Risk Level | Medium-High |
| Tracking / Ownership | Primary Watchlist / Owned |

**Decision rationale:** PFE is **Hold / Watch** at $30.11, with -2.6% probability-weighted upside and -48.2% bear-case return. The investment case rests on replacing patent-expiry exposure, improving acquired-product returns and preserving cash generation. Confidence is 57/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

## Investment Thesis

The investment case rests on replacing patent-expiry exposure, improving acquired-product returns and preserving cash generation. Q2 revenue was about $15 billion; non-COVID revenue grew 5% operationally and launched or acquired products 18%. The low adjusted earnings multiple and dividend are attractive only if sustainable cash earnings cover investment, debt service and distributions through the patent cycle.

### What the Market May Be Mispricing

| Debate | Research judgment |
|---|---|
| Pipeline approvals and patent-expiry replacement | The investment case rests on replacing patent-expiry exposure, improving acquired-product returns and preserving cash generation. |
| Acquired-product commercial returns | Product-level demand, net realized price, payer access, treatment duration and clinical differentiation determine returns. |
| Debt reduction and dividend coverage | Q2 reported EPS was negative after $4.3 billion of intangible impairments, while adjusted EPS was $0.77. |

## Business Overview

Pfizer develops and sells branded medicines and vaccines across oncology, primary and specialty care. Patents and clinical evidence support pricing for finite periods, after which generic or biosimilar competition can erode revenue. Seagen expanded oncology assets and development capabilities. COVID products remain commercially relevant but no longer provide a reliable basis for valuing normalized group earnings.

### Business Takeaway

Pfizer develops and sells branded medicines and vaccines across oncology, primary and specialty care. Product-level demand, net realized price, payer access, treatment duration and clinical differentiation determine returns.

## Industry, TAM & Market Share

Drug demand is durable, but individual product economics are bounded by patents, reimbursement and clinical outcomes. Pricing regulation and payer bargaining constrain monetization. A large disease population is not a probability-adjusted drug revenue forecast; pipeline assets require indication-specific evidence.

### Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| Merck (MRK) | Segment-specific: indication-dependent oncology treatments and trials | Product scope; no matched operating-scale series | Compare treatment line, label and evidence | Customer choice in the stated segment only |
| Bristol Myers Squibb (BMY) | Segment-specific: oncology and selected specialty indications | Product scope; no matched operating-scale series | Competition is drug and indication specific | Customer choice in the stated segment only |
| Moderna; GSK | Segment-specific: overlapping vaccine indications | Product scope; no matched operating-scale series | Separate vaccine competition from oncology | Customer choice in the stated segment only |

### Industry Takeaway

A large disease population is not a probability-adjusted drug revenue forecast; pipeline assets require indication-specific evidence. The base case requires evidence of profitable adoption within that market.

## Customer Economics

Product-level demand, net realized price, payer access, treatment duration and clinical differentiation determine returns. R&D and acquisition spending are necessary portfolio replacement costs, not discretionary expenses that can disappear indefinitely. Pipeline success must be measured after failed trials and capital invested.

### Customer-Economics Takeaway

The economic test is Debt reduction and dividend coverage. Pipeline success must be measured after failed trials and capital invested.

## Competitive Landscape & Moat

### Competitive Landscape

Pharmaceutical competition is drug-, indication- and treatment-line-specific. Consolidated patent-cliff profiles are financial context, not proof that entire product portfolios compete.

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| Merck (MRK) | No consistent comparable series | Segment-specific: indication-dependent oncology treatments and trials | Established oncology clinical franchise | Products are not substitutable in every indication | Compare treatment line, label and evidence |
| Bristol Myers Squibb (BMY) | No consistent comparable series | Segment-specific: oncology and selected specialty indications | Existing therapies and clinical development | Different molecules, labels and patent calendars | Competition is drug and indication specific |
| Moderna; GSK | No consistent comparable series | Segment-specific: overlapping vaccine indications | Competing vaccine platforms and commercial distribution | Only shared indications and eligible populations overlap | Separate vaccine competition from oncology |

### Moat Assessment

Patents, clinical data, manufacturing and global distribution create a meaningful but continually expiring moat. The group must replenish differentiation through successful research or acquisitions. Pipeline breadth does not ensure enough commercially valuable approvals.

**Moat direction:** Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

### Competitive Takeaway

Patents, clinical data, manufacturing and global distribution create a meaningful but continually expiring moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2024 | 63,627 | 6.84% | 72.98% | 24.45% | 9,835 | 15.46% | 877 | 5,700 | 20,477 | 67,418 |
| FY2025 | 62,579 | -1.65% | 75.81% | 30.62% | 9,075 | 14.50% | 799 | 5,713 | 13,596 | 67,647 |
| Q1 FY2026 | $14,451 | N/D | N/D | N/D | $2,179 (derived: CFO - capex) | 15.1% | $272 | 5,731 | $1,703 | N/D |
| Q2 FY2026 | $15,034 | N/D | N/D | N/D | $302 (derived: current YTD - prior YTD) | 2.0% | $249 (derived: current YTD - prior YTD) | 5,699 | $976 | N/D |
| H1 FY2026 | $29,484 | N/D | N/D | N/D | $2,481 (derived: CFO - capex) | 8.4% | $521 | 5,733 | $976 | N/D |
| Q3 FY2026 | $16,583 | N/D | N/D | N/D | $4,802 (derived: current YTD - prior YTD) | 29.0% | $362 (derived: current YTD - prior YTD) | 5,751 | $1,824 | N/D |
| 9M FY2026 | $46,067 | N/D | N/D | N/D | $7,283 (derived: CFO - capex) | 15.8% | $883 | 5,739 | $1,824 | N/D |

### Financial Takeaways

Q2 reported EPS was negative after $4.3 billion of intangible impairments, while adjusted EPS was $0.77. TTM FCF was approximately $11.0 billion and debt substantial. The model uses sustainable after-cost EPS and includes an assumed annual dividend stream; impairment exclusions do not erase the capital previously spent on acquired assets.

**Financial direction:** Mixed — assess the reported trend alongside dilution and the balance sheet.

## Management & Capital Allocation

Capital allocation has been mixed, with major acquisitions and post-COVID normalization requiring a demanding return test. Cost savings can help, but cannot replace successful medicines. Monitor oncology launches, key late-stage readouts, debt reduction and dividend coverage.

### Management Takeaway

Monitor oncology launches, key late-stage readouts, debt reduction and dividend coverage.

## Valuation

### Current Valuation

| Metric | Value |
|---|---|
| Price Snapshot | $30.00 — 2026-11-03 regular-session close, America/New_York |
| Market Capitalization | $171.62B |
| Enterprise Value | $223.39B |
| Trailing P/E | 39.58 |
| Provider forward P/E | 10.92 |
| EV / Sales | 3.51 |

### Comparable Company Analysis

| Company | Relevance | Public / Private | Forward P/E | EV / Sales | Growth / Margin / Risk Context |
|---|---|---|---|---|---|
| PFE — Pfizer Inc. | Subject company | Public | 10.92 | 3.51 | pharmaceuticals; 3Y revenue-growth estimate -4.18%; operating margin 29.58% |
| MRK — Merck | Selected oncology overlap; indication-specific, diversified group multiple | Public | 17.82 | 6.20 | innovative medicines and oncology; 3Y revenue-growth estimate 4.60%; operating margin 35.28% |
| BMY — Bristol Myers Squibb | Selected oncology/specialty overlap; different patent portfolio | Public | 10.09 | 3.24 | innovative medicines and patent expirations; 3Y revenue-growth estimate -5.07%; operating margin 31.79% |
| Moderna; GSK | Segment-specific: overlapping vaccine indications | Public | N/D — no matched snapshot collected | N/D — no matched snapshot collected | Separate vaccine competition from oncology |

**Comparable takeaway:** Pharmaceutical competition is drug-, indication- and treatment-line-specific. Consolidated patent-cliff profiles are financial context, not proof that entire product portfolios compete. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 12×, versus the provider's current forward P/E of 10.92×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of **$27.40**, versus the central base FV of **$29.71**. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

### Valuation Scenarios

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---|---|---|---|
| Bear | 3Y revenue CAGR -2%; sustainable 2029 EPS $1.80 after compensation; 9× P/E; 12% discount rate; Pipeline disappointments and erosion limit 2029 sustainable EPS to $1.80. | $15.61 | 30% | Execution, financing or competitive setbacks remain credible | -48.0% |
| Base | 3Y revenue CAGR 2%; sustainable 2029 EPS $3.00 after compensation; 12× P/E; 12% discount rate; New products offset enough losses to support $3 of 2029 sustainable EPS. | $29.71 | 50% | Most likely operating trajectory, requiring measurable progress | -1.0% |
| Bull | 3Y revenue CAGR 6%; sustainable 2029 EPS $4.20 after compensation; 15× P/E; 12% discount rate; Oncology and other launches succeed, producing $4.20 of 2029 sustainable EPS. | $48.93 | 20% | Successful product conversion and operating leverage; not assured | +63.1% |
| **Probability-Weighted** | Sum of each scenario value × its probability | $29.32 | **100%** | Judgmental scenario probabilities | -2.3% |

### Valuation Takeaway

- **Primary valuation method:** Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
- **Cross-check methods:** Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in [the valuation workpaper](../valuation/watchlist_models_2026-10-21.md).
- **Key valuation dependencies:** Pipeline approvals and patent-expiry replacement; Acquired-product commercial returns; Debt reduction and dividend coverage. All forward figures are independent research assumptions, not company guidance or consensus.
- **Valuation confidence / Risk Level:** 57/100 / Medium-High. Scenario values are sensitive to sustainable earnings and terminal multiples.
- **Margin-of-safety conclusion:** Hold / Watch at $30.11. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

## Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Evan Seigerman / BMO Capital Markets | What drives the design of the prostate-cancer trial? | Management said the study is designed around clinically meaningful benefit. | Value the opportunity only as permissions and evidence mature. |
| Chris Schott / JPMorgan | What supports the higher non-COVID outlook? | Management said product momentum supports the higher guidance. | Treat the stated timetable as conditional on demonstrated execution. |
| Umer Raffat / Evercore ISI | How does global ownership affect the EZH2 opportunity? | Management said global ownership broadens the economics. | Confirm that this opportunity converts into profitable recurring demand. |
| Geoff Meacham / Citibank | When is the next controlled readout for obesity combinations expected? | Management said the next controlled readout is expected in 2027. | Confirm that this opportunity converts into profitable recurring demand. |
| Akash Tewari / Jefferies | What evidence is available on breast-cancer efficacy? | Management said detailed trial data are still pending. | Confirm that this opportunity converts into profitable recurring demand. |
| Terence Flynn / Morgan Stanley | How durable is the dividend commitment? | Management reiterated its commitment to the dividend. | Confirm that this opportunity converts into profitable recurring demand. |
| Trung Huynh / RBC | What supports the immunology pipeline? | Management said multiple mechanisms support the pipeline. | Confirm that this opportunity converts into profitable recurring demand. |
| Steve Scala / TD Cowen | How will the product be compared with Dupixent? | Management said a superiority trial is planned. | Confirm that this opportunity converts into profitable recurring demand. |
| Asad Haider / Goldman Sachs | How will Pfizer address COVID normalization and the patent cliff? | Management said pipeline investment targets growth after the patent cliff. | Confirm that this opportunity converts into profitable recurring demand. |

### Analyst-Q&A Takeaway

Pipeline readouts offer renewal opportunities while COVID and patent expirations remain pressure points. Trial design and dividend commitments are not substitutes for realized replacement earnings and deleveraging.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| Pipeline approvals and patent-expiry replacement | The investment case rests on replacing patent-expiry exposure, improving acquired-product returns and preserving cash generation. | Revenue trajectory sustains approximately 2% annual growth on a comparable basis | Growth remains below the -2% bear assumption over a full operating cycle | Revenue outlook and scenario probabilities |
| Acquired-product commercial returns | Product-level demand, net realized price, payer access, treatment duration and clinical differentiation determine returns. | After-cost earnings progress toward the base implied net margin of 25.3% | Competition, credit losses or service costs make that margin trajectory unattainable | Margins, moat score and valuation multiple |
| Debt reduction and dividend coverage | Q2 reported EPS was negative after $4.3 billion of intangible impairments, while adjusted EPS was $0.77. | Financing and compensation remain consistent with 5,700.0M economic shares in the 2029 base case | Required capital or cumulative dilution materially exceeds the model without matching earnings | Financial score, confidence and downside value |

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---|---|---|---|
| Business durability and economics | 81 | 25% | 20.3 | Product-level demand, net realized price, payer access, treatment duration and clinical differentiation determine returns. |
| Moat and competitive position | 77 | 25% | 19.3 | Patents, clinical data, manufacturing and global distribution create a meaningful but continually expiring moat. |
| Growth runway and durability | 55 | 20% | 11.0 | Drug demand is durable, but individual product economics are bounded by patents, reimbursement and clinical outcomes. |
| Financial quality and balance sheet | 65 | 15% | 9.8 | Q2 reported EPS was negative after $4.3 billion of intangible impairments, while adjusted EPS was $0.77. |
| Management, governance and capital allocation | 53 | 15% | 7.9 | Capital allocation has been mixed, with major acquisitions and post-COVID normalization requiring a demanding return test. |
| **Quality Score** | **68.2** | **100%** | **68.2** | Weighted score, independent of ownership and current price |

- **Quality Tier:** B
- **Speculative override:** None

### Opportunity Score

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---|---|---|
| Quality | 68.2 | 68.2 | 30% | 20.5 |
| Probability-weighted upside | -2.3% | 45.5 | 35% | 15.9 |
| Bear-case downside | -48.0% | 2.0 | 20% | 0.4 |
| Risk / valuation confidence | 57 | 57.0 | 15% | 8.5 |
| **Opportunity Score** |  | **45.3** | **100%** | **45.3** |

- **Opportunity Rank:** #51 of 76
- **Zone Status:** Hold / Watch

## Portfolio Context

- **Tracking tier:** Primary Watchlist
- **Owned:** Yes
- **Tracking source of truth:** `my_watchlist.md`
- **Portfolio source of truth:** `portfolio/holdings.md`
- **Scoring independence:** Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 (America/New_York) | $30.11 | Hold / Watch | Hold / Watch | >$17.17–$23.46 | ≤ $17.17 | > $32.58 | $29.71 | $29.32 | -2.6% | 68.2 | 45.1 / #44 | Initial missing-file analysis; common-universe ranking; independent scenario assumptions |

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [www.sec.gov](https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm) | Company IR / earnings filing | Q2 2026 | Latest operating results, guidance, products and financial supplement |
| [PFE complete earnings-call transcript](https://stockanalysis.com/stocks/pfe/transcripts/660655-q2-2026/) | Transcript | Q2 2026 | Prepared remarks and all material Q&A exchanges |
| [PFE regular-session historical price](https://stockanalysis.com/stocks/pfe/history/) | Market data | 2026-10-20 close | Common price used in returns, scores and zones |
| [PFE valuation statistics](https://stockanalysis.com/stocks/pfe/statistics/) | Market data | 2026-10-20 close; ratios retrieved 2026-10-21 | Market capitalization, shares, quoted multiples and current ratios |
| [PFE historical income statement](https://stockanalysis.com/stocks/pfe/financials/income-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical income statement; source-native currency and definitions |
| [PFE historical balance sheet](https://stockanalysis.com/stocks/pfe/financials/balance-sheet/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical balance sheet; source-native currency and definitions |
| [PFE historical cash flows](https://stockanalysis.com/stocks/pfe/financials/cash-flow-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical cash flows; source-native currency and definitions |
| [Merck statistics](https://stockanalysis.com/stocks/mrk/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [Bristol Myers Squibb statistics](https://stockanalysis.com/stocks/bmy/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [SEC XBRL company facts — PFE](https://data.sec.gov/api/xbrl/companyfacts/CIK0000078003.json) | Regulatory filing (as tagged) | FY2026, through 2026-09-27 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |